Free tool
FAERS Monitor: Besivance
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022308 or its brand name (Besivance, Besifloxacin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
969
Serious
423
44% of reports
Hospitalization
157
Death reported
67
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain104
- vision blurred82
- eye irritation79
- off label use78
- hypersensitivity68
- ocular hyperaemia60
- cardiac disorder50
- chronic kidney disease42
- drug ineffective36
- photophobia36
- impaired healing34
- foreign body sensation in eyes33
- corneal oedema30
- cataract29
- visual impairment29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 16 |
| 2010 | 62 |
| 2011 | 43 |
| 2012 | 44 |
| 2013 | 22 |
| 2014 | 42 |
| 2015 | 70 |
| 2016 | 87 |
| 2017 | 106 |
| 2018 | 103 |
| 2019 | 81 |
| 2020 | 61 |
| 2021 | 53 |
| 2022 | 65 |
| 2023 | 57 |
| 2024 | 36 |
| 2025 | 13 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| corneal oedemaSignal | 30 | 294.5 | 206.6 | 8,372 |
| foreign body sensation in eyesSignal | 33 | 112.9 | 80.7 | 3,533 |
| photophobiaSignal | 36 | 41.6 | 30.2 | 1,385 |
| eye painSignal | 104 | 40.1 | 33.4 | 3,928 |
| eye irritationSignal | 79 | 29.8 | 24.1 | 2,176 |
| ocular hyperaemiaSignal | 60 | 27.5 | 21.5 | 1,506 |
| impaired healingSignal | 34 | 22.5 | 16.2 | 678 |
| vision blurredSignal | 82 | 13.0 | 10.5 | 899 |
| chronic kidney diseaseSignal | 42 | 12.0 | 8.9 | 414 |
| cardiac disorderSignal | 50 | 11.6 | 8.9 | 476 |
| cataractSignal | 29 | 10.6 | 7.4 | 243 |
| hypersensitivitySignal | 68 | 8.0 | 6.3 | 410 |
| visual impairmentSignal | 29 | 5.1 | 3.5 | 92 |
| off label use | 78 | 1.9 | 1.6 | 36 |
| drug ineffective | 36 | 0.6 | 0.4 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.